Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spain's Sabadell mulls potential sale of TSB

(Sharecast News) - Banco Sabadell is exploring a potential sale of high street lender TSB, the Spanish bank confirmed on Tuesday. In a brief statement following widespread media reports, the lender said it had received "preliminary non-binding expressions of interest for the acquisition of the entire share capital of TSB" and confirmed it would weigh up any potential binding offer.

On Monday, the Financial Times reported that Sabadell - which is seeking to fend off a €11bn hostile takeover from Spanish rival BBVA - was working with advisors to examine offloading the British bank.

Sabadell acquired TSB from Lloyds Banking Group in 2015 for £1.7bn. The acquisition was part of a broader plan to diversify away from Spain, much in the same vein as rival Santander. The last year, however, has seen Sabadell focus on fending off BBVA's approach.

That deal would see the combined business overtake Santander to become the second-largest player in domestic lending. The government is currently reviewing the bid.

Most of the UK's high street lenders could be interested in TSB, including Santander, which has long had presence in the country after acquiring building societies Abbey National in 2004, Bradford & Bingley in 2008 and Alliance & Leicester in 2009.

Other lenders who could be interested include NatWest Group, Barclays and HSBC, the FT noted. It is not known who has approached Sabadell. The newspaper also quoted an unnamed source saying a sale could potentially generate between £1.7bn and £2bn.

TSB, which has around 5m UK customers and 175 branches, posted pre-tax profits of £285m last year on income of £1.14bn. Total assets stood at £46.1bn as at the end of 2024.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.